Edition:
United States

People: Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

33.72USD
19 Aug 2019
Change (% chg)

-- (--)
Prev Close
$33.72
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
685,257
52-wk High
$34.02
52-wk Low
$10.41

Given, Bruce 

Dr. Bruce D. Given is the Chief Operating Officer of Arrowhead Pharmaceuticals, Inc. Dr. Given was a member of the Board of Directors for ICON, plc. from 2004 until his retirement in 2013 and Chairman of its Board of Directors from 2010 to 2013. Dr. Given served as the President and Chief Executive Officer, and as a member of the Board of Directors of Encysive Pharmaceuticals, an R&D-based commercial pharmaceutical company, roles he held from 2002 through 2007. Subsequent to his tenure at Encysive until 2011, Dr. Given was President of Bruce Given Consulting, a firm that provides consulting services to biotech companies. Since October 1, 2009, Dr. Given has been a director of Calando Pharmaceuticals, Inc., and from February 2010 until its dissolution in October 2014, Dr. Given was the Chief Executive Officer of Leonardo Biosystems, Inc., in which Arrowhead held a minority equity interest. Prior to his tenure at Encysive, Dr. Given held several senior executive roles at Johnson and Johnson, Sandoz Pharmaceuticals and Schering-Plough. Dr. Given obtained his bachelor of sciences degree from Colorado State University, graduating Phi Beta Kappa. He received his M.D. degree with honors from the University of Chicago, Pritzker School of Medicine and completed his medical training at the University of Chicago and at Brigham and Women’s Hospital in Boston, where he was a Clinical Fellow at Harvard Medical School. He is board certified in internal medicine and endocrinology and metabolism and has authored 33 scientific publications. Dr. Bruce Given is a brother of Dr. Douglass Given, a director of the company.

Basic Compensation

Total Annual Compensation, USD 896,262
Restricted Stock Awards, USD 644,000
Long-Term Incentive Plans, USD --
All Other, USD 11,799
Fiscal Year Total, USD 1,552,060

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Douglass Given

189,150

Christopher Anzalone

1,619,900

Kenneth Myszkowski

853,018

Bruce Given

1,552,060

Patrick O'Brien

823,295

Michael Perry

178,650
As Of  29 Sep 2018